Holding(s) in Company

RNS Number : 8771I
N4 Pharma PLC
13 August 2019
 

13 August 2019

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Holdings in Company

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces that it has been notified that, following a purchase of 112,258 ordinary shares of 0.4p each in the company ("Ordinary Shares") earlier today, Mr David Farrier is now beneficially interested in 12,175,510 Ordinary Shares, representing 12.0 per cent. of the Company's issued share capital.

 

Enquiries:

 

N4 Pharma Plc

Nigel Theobald, CEO

 

Via Scott PR

 

Allenby Capital Limited

James Reeve/Asha Chotai

 

Tel: +44(0)203 328 5656

Scott PR

Georgia Smith

 

 

Tel: +44(0)1477 539 539

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLLLFLITSIVLIA

Companies

N4 Pharma (N4P)
UK 100

Latest directors dealings